Amgen Inc. [AMGN] stock Initiated by SVB Leerink analyst, price target now $256

Amgen Inc. [NASDAQ: AMGN] traded at a low on 08/30/22, posting a -0.11 loss after which it closed the day’ session at $239.12. The company report on August 30, 2022 that AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer.

Detailed Data to be Presented at an Upcoming Medical Congress.

The results of the trading session contributed to over 3662292 shares changing hands. Over the past one week, the price volatility of Amgen Inc. stands at 1.30% while the volatility over the past one month is 1.47%.

The market cap for AMGN stock reached $130.59 billion, with 535.00 million shares outstanding and 533.13 million shares in the current float. Compared to the average trading volume of 2.95M shares, AMGN reached a trading volume of 3662292 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Amgen Inc. [AMGN]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMGN shares is $253.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMGN stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

SVB Leerink have made an estimate for Amgen Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on May 23, 2022. While these analysts kept the previous recommendation, Wells Fargo raised their target price from $210 to $250. The new note on the price target was released on February 09, 2022, representing the official price target for Amgen Inc. stock. Previously, the target price had yet another raise from $272 to $285, while Oppenheimer kept a Outperform rating on AMGN stock. On February 09, 2022, analysts increased their price target for AMGN shares from 235 to 238.

The Average True Range (ATR) for Amgen Inc. is set at 3.75, with the Price to Sales ratio for AMGN stock in the period of the last 12 months amounting to 4.95. The Price to Book ratio for the last quarter was 52.90, with the Price to Cash per share for the same quarter was set at 13.15. Price to Free Cash Flow for AMGN in the course of the last twelve months was 30.74 with Quick ratio for the last quarter at 1.20.

How has AMGN stock performed recently?

Amgen Inc. [AMGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.19. With this latest performance, AMGN shares dropped by -2.65% in over the last four-week period, additionally plugging by 6.18% over the last 6 months – not to mention a rise of 6.69% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMGN stock in for the last two-week period is set at 35.65, with the RSI for the last a single of trading hit 28.79, and the three-weeks RSI is set at 40.12 for Amgen Inc. [AMGN]. The present Moving Average for the last 50 days of trading for this stock 246.45, while it was recorded at 241.86 for the last single week of trading, and 235.19 for the last 200 days.

Amgen Inc. [AMGN]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Amgen Inc. [AMGN] shares currently have an operating margin of +35.22 and a Gross Margin at +75.16. Amgen Inc.’s Net Margin is presently recorded at +22.68.

Return on Equity for this stock inclined to 73.16, with Return on Assets sitting at 9.50.

Amgen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.

Earnings analysis for Amgen Inc. [AMGN]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amgen Inc. go to 8.03%.

Insider trade positions for Amgen Inc. [AMGN]

There are presently around $100,011 million, or 80.10% of AMGN stock, in the hands of institutional investors. The top three institutional holders of AMGN stocks are: BLACKROCK INC. with ownership of 46,825,552, which is approximately -6.402% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 46,148,617 shares of the stock with an approximate value of $11.04 billion in AMGN stocks shares; and STATE STREET CORP, currently with $7.0 billion in AMGN stock with ownership of nearly -4.011% of the company’s market capitalization.

Positions in Amgen Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 1,063 institutional holders increased their position in Amgen Inc. [NASDAQ:AMGN] by around 19,787,570 shares. Additionally, 1,023 investors decreased positions by around 26,877,162 shares, while 362 investors held positions by with 371,583,366 shares. The mentioned changes placed institutional holdings at 418,248,098 shares, according to the latest SEC report filing. AMGN stock had 133 new institutional investments in for a total of 1,841,266 shares, while 85 institutional investors sold positions of 1,895,821 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here